The global e-clinical solutions market size is expected to be worth around US$ 22.7 billion by 2030, according to a new report by Vision Research Reports.
The global e-clinical solutions market size was valued at US$ 7.9 billion in 2020 and is anticipated to grow at a CAGR of 13.7% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38878
Table of Contents
E-Clinical Solutions Market Growth Factors
Increasing R&D activities by biopharma and pharma companies, application of software solutions in clinical trials, and expanding customer base are anticipated to fuel market growth. During the COVID-19 pandemic, clinical laboratories experienced high demand for COVID-19 tests. eClinical solutions, such as the clinical data management systems assisted these laboratories to seamlessly manage a huge influx of specimens on a daily basis.
Increasing research and development activities by biopharma and pharma companies is one of the key trends escalating market growth. Besides this, the growing incorporation of software solutions in clinical trials is also projected to drive the market for eClinical solutions.
E-Clinical Solutions Market Report Coverage
Report Scope | Details |
Market Size | USD 22.7 Billion by 2030 |
Growth Rate | CAGR of 13.7% From 2021 to 2030 |
Base Year | 2021 |
Forecast Period | 2021 to 2030 |
Segments Covered | Product, delivery mode, development phase, end-use |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Mentioned | Datatrak International, Inc.; Oracle; Parexel International Corporation; Dassault Systemes; Bioclinica; Datatrak International, Inc.; CRF Health; ERT Clinical; eClinicalWorks; IBM; Anju Life Sciences Software; eClinical Solutions |
By Product Analysis
The CTMS segment dominated the market for eClinical solutions and accounted for the largest revenue share of 20.9% in 2020. eCOA is estimated to be the fastest-growing segment during the forecast period owing to the rising significance of high-quality clinical data.
Elimination of data variance risk streamlined information and lowering of site monitoring cost are key advantages associated with eCOA. These aforementioned benefits are expected to fuel its demand in the coming years.
By Delivery Mode Analysis
The web-hosted segment dominated the market for eClinical solutions and accounted for the largest revenue share of around 75.2% in 2020. The dominance of the segment can be attributed to associated benefits such as easy accessibility, usability, and lower investments required.
The cloud-based segment is anticipated to exhibit an exponential CAGR of 14.3% during the forecast period owing to integrated features such as flexibility, high accessibility, negligible handling costs, and easy data backup.
By Development Phase Analysis
On the basis of the development phase, the phase III segment dominated the market for eClinical solutions and accounted for the largest revenue share of 52.9% in 2020. The spiraling need for the incorporation of clinical data management software to curb overall cost and improve process efficiency is contributing to the growth of the segment.
The phase I segment is estimated to be the most promising segment during the forecast period owing to the high significance of these systems to predict future outcomes and eliminate drug candidates possessing the least probability of success.
By End-use Analysis
The CROs segment dominated the market for eClinical solutions and held the largest revenue share of 37.8% in 2020. The segment is projected to rise at a remarkable CAGR during the forecast period owing to the growing inclination of pharmaceutical companies to reduce overall expenditure.
Benefits involved in outsourcing clinical trials to CROs are responsible for the heightened growth of this segment. These benefits include cost advantages, increased efficiency of services, enhanced productivity, and a higher focus on core areas of development critical to a company’s growth.
By Regional Analysis
North America dominated the eClinical solutions market and accounted for the largest revenue share of 53.1% in 2020. The increasing target population, coupled with the rising prevalence of lifestyle-associated diseases such as diabetes and cardiac disorders, is poised to stimulate the growth of the market.
In Asia Pacific, the market for eClinical solutions is likely to register a noteworthy CAGR at 15.5% over the forecast period. High unmet medical needs and the rising prevalence of target chronic diseases such as cancer, cardiovascular conditions, and infectious diseases are stoking the demand for software solutions in the region.
Read also @ Dental Diagnostic And Surgical Equipment Market Revenue To Cross USD 20.7 Bn by 2030
Major Key Players Covered in The E-Clinical Solutions Market Report include
- Datatrak International, Inc.
- Oracle
- Parexel International Corporation
- Dassault Systemes
- Bioclinica
- Datatrak International, Inc.
- CRF Health
- ERT Clinical
- eClinicalWorks
- IBM
- Anju Life Sciences Software
- eClinical Solutions
E-Clinical Solutions Market Segmentation
- By Product
- Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)
- Clinical Trial Management Systems (CTMS)
- Clinical Analytics Platforms
- Randomization and Trial Supply Management (RTSM)
- Clinical Data Integration Platforms
- Electronic Clinical Outcome Assessment (eCOA)
- Safety Solutions
- Electronic Trial Master File (eTMF)
- By Delivery Mode
- Web-hosted (On demand)
- Licensed Enterprise (On premise)
- Cloud-based
- By Development Phase
- Phase I
- Phase II
- Phase III
- Phase IV
- By End-use
- Hospitals/Healthcare providers
- CROs
- Academic Institutes
- Pharma & Biotech Organizations
- Medical Device Manufacturers
- Regional
- North America
- U.S.
- Canada
- Mexico
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Netherlands
- Sweden
- Denmark
- Asia Pacific
- Japan
- China
- India
- South Korea
- Australia
- New Zealand
- Taiwan
- Hong Kong
- Singapore
- Thailand
- Vietnam
- Central & South America
- Brazil
- Argentina
- Chile
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Qatar
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. E-Clinical Solutions Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Development Phase Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. E-Clinical Solutions Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global E-Clinical Solutions Market, By Product
7.1. E-Clinical Solutions Market, by Product, 2021-2030
7.1.1. Electronic Data Capture (EDC) and Clinical Data Management Systems (CDMS)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Clinical Trial Management Systems (CTMS)
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Clinical Analytics Platforms
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Randomization and Trial Supply Management (RTSM)
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Clinical Data Integration Platforms
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Electronic Clinical Outcome Assessment (eCOA)S)
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Safety Solutions
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Electronic Trial Master File (eTMF)
7.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global E-Clinical Solutions Market, By Delivery Mode
8.1. E-Clinical Solutions Market, by Delivery Mode, 2021-2030
8.1.1. Web-hosted (On demand)
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Licensed Enterprise (On premise)
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Cloud-based
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global E-Clinical Solutions Market, By Development Phase
9.1. E-Clinical Solutions Market, by Development Phase, 2021-2030
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global E-Clinical Solutions Market, By End-user
10.1. E-Clinical Solutions Market, by End-user, 2021-2030
10.1.1. Hospitals/Healthcare providers
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. CROs
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Academic Institutes
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Pharma & Biotech Organizations
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Medical Device Manufacturers
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global E-Clinical Solutions Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.1.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.1.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.1.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.2.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.2.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.2.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.2.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.2.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.3.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.3.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.3.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.3.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.3.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.4.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.4.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.4.6.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.4.7.4. Market Revenue and Forecast, by End-user (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Product (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.4.8.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.5.5.4. Market Revenue and Forecast, by End-user (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Product (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Delivery Mode (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Development Phase (2017-2030)
11.5.6.4. Market Revenue and Forecast, by End-user (2017-2030)
Chapter 12. Company Profiles
12.1. Datatrak International, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Oracle
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Parexel International Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Dassault Systemes
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bioclinica
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Datatrak International, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. CRF Health
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. ERT Clinical
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. eClinicalWorks
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. IBM
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38878
Contact Us:
Vision Research Reports
Call: +1 9197 992 333